secwatch.observer — SEC 8-K summary
======================================

Issuer:     Schrodinger, Inc. (SDGR)
CIK:        0001490978
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001490978-25-000116
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Schrödinger Q3 revenue up 54% to $54.3M; software growth 28%, FY guidance trimmed
--------------------------------------------------------------------------------

- Total revenue $54.3M (+54% YoY); software revenue $40.9M (+28%); drug discovery $13.5M.
- GAAP net loss narrowed to $32.8M from $38.1M; non-GAAP net loss $42.3M (was $63.7M).
- FY2025 software revenue growth guidance cut to 8-13% (from 10-15%); drug discovery raised to $49-52M.
- Shift to discovery-focused R&D; not advancing programs independently, expects ~$70M savings.
- SGR-1505 got Orphan Drug Designation; SGR-6016 selected as development candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1490978/000149097825000116/0001490978-25-000116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1490978/000149097825000116/sdgr-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001490978-25-000116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer